NSE: STAR | BSE: 532531

Strong Performer, Under Radar

Download real time

894.45 -5.05 (-0.56%)

44.62% Fall from 52W High

247.3K NSE+BSE Volume

NSE 03 Dec, 2025 3:59 PM (IST)

8,244.4

Market Cap

Above industry Median

Beta 1Year

Very High Volatility

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

11 Feb 2018

894.45

-0.56%

Strides Shasun: Weak results; new launches to drive operating performance

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

We reduce our sales estimates by 25%/29%/28% and PAT estimates by 61%/35%/28% for FY18/19/20 to factor (1) demerger of commodity API business, (2) lower than expected operating margin in3QFY18, and (3) delay in procurement with respect to institutional business.There is a risk of increased price erosion in recently-launched molecules;however pipeline remains robust for better growth, subject to approval. We value STR on sum-of-the-parts (SOTP), valuing the p harma business at 18x12M forward earnings (industry average P/E multiple for midcap pharma)and Solara at an EV of 8x (from 12x earlier to factor commodity nature of API business) FY19E EBITDA to arrive at a price target of INR989. Reiterate Buy

Strides Pharma Science Ltd. is trading below its 30 day SMA of 900.9

Strides Pharma Science Ltd.

21 Nov 2017

894.45

-0.56%

Strides Shasun (Update): Another good deal. Maintain BUY

Buy: Strides Pharma Science Ltd.

HDFC Securities

Re-iterate BUY with a TP of Rs 1,200 (18x Sep19E + Rs 100/sh for Solara + Rs 30/sh for Biopharma). In another business restructuring, Strides Shasun (STR) has sold its India-branded business to Eris Life Sciences, for a consideration of Rs 5bn. The business contributed only ~5% to the total topline in FY17, and would have required significant investment to scale it up further. This is the second such business rationalisation by STR in FY18, along with the hive-off of the commodity API business. We believe that these divestments would help narrow STRs focus on the high potential business segments, i.e. the US and Australia, where investments are now complete, and strong growth is expected to kick-in over FY18-20E.

Strides Pharma Scien.. has an average target of 1085.00 from 1 broker.

Strides Pharma Science Ltd.

20 Nov 2017

894.45

-0.56%

Strides Shasun: Divestment to focus on profitable businesses

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Transaction details: Strides Shasun (STR) has entered into definitive agreement with Eris Lifesciences for sale of domestic branded formulation business for cash consideration of INR5b. In this transaction, STR would divest portfolio of 130+ brands along-with employees forming part of the domestic branded business. STR would retain global rights of these products. The transaction is subject to customary closing...

Strides Pharma Science Ltd. is trading below its 30 day SMA of 900.9

Strides Pharma Science Ltd.

07 Nov 2017

894.45

-0.56%

Result Update:Strides Shasun

Buy: Strides Pharma Science Ltd.

Target

Axis Direct

Q2 revenue growth (18% YoY) was in line, but EBITDA declined 15% YoY (12% below our expectations) on lower gross margin of 51.4% (down 570 bps YoY) and higher other expenses. Gross margin declined due to lower contribution of higher margin anti-malaria tender sales, and higher sales of lower margin

Strides Pharma Science Ltd. is trading above its 200 day SMA of 792.1

Strides Pharma Science Ltd.

01 Nov 2017

894.45

-0.56%

Strides Shasun (2QFY18): Extended pit stop. Maintain BUY

Buy: Strides Pharma Science Ltd.

HDFC Securities

Maintain BUY with a TP of Rs 1,200 (18x Sep19E + Rs 100/sh for Solara + Rs 30/sh for biopharma). Strides Shasuns (STR) 2QFY18 performance was an improvement over 1QFY18. However, the YoY performance remained subdued. Total revenues grew ~14% YoY to ~Rs 10bn. Sequential growth was higher at ~18%. This was driven by a ~21% QoQ jump in regulatory market sales. EBITDA came in at ~Rs 1.3bn (-15% YoY), and the margin was 13.2%, down ~450bps YoY. Although there was a sequential improvement, it was lower than expectations. PAT came in at Rs 215mn, down ~75% YoY, leaving a long way to go to achieve our FY18 estimate of ~Rs 3.1bn.

Strides Pharma Science Ltd. is trading below its 30 day SMA of 900.9

Strides Pharma Science Ltd.

31 Oct 2017

894.45

-0.56%

Strides Shasun: Gradual sequential improvement in operating performan

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Shasun's (STR) 2QFY18 sales of INR10b were better than our estimate of INR8.9b. EBITDA margin of 13.2% missed our estimate of 14.5%. Adjusted PAT of INR253m too was lower than our estimate of INR439m. Regulated market and branded generics drive sales growth: Sales grew 4.4% YoY (+18.2% QoQ) to INR10b for the quarter. With a trough formed in 1QFY18, there has been increased business from the regulated market, and also from branded generics in the emerging market. Weak institutional business in the emerging market affected overall growth for the quarter....

Strides Pharma has lost -43.84% in the last 1 Year

Strides Pharma Science Ltd.

16 Oct 2017

894.45

-0.56%

Strides Shasun (Initiating Coverage): Specialist in wealth creation. BUY

Buy: Strides Pharma Science Ltd.

HDFC Securities

Initiate coverage with BUY rating and a TP of Rs 1,200 (18x Sep-19E + Rs 100/sh for Solara + Rs 30/sh for the biopharma investments). Over the last decade, Strides Shasun (STR) has given its shareholders a phenomenal ~30% compounded annual return. Capital invested in Oct-07 would have grown ~10x today. While STRs aggressive M&A; activity can be viewed negatively in-terms of capital allocation, its track record of value creation cannot be questioned. The companys philosophy on this remains unchanged and its focus remains firmly on enhancing shareholder wealth.

Strides Pharma Scien.. has an average target of 1085.00 from 1 broker.

Strides Pharma Science Ltd.

18 Aug 2017

894.45

-0.56%

Result Update - Strides Shasun

Buy: Strides Pharma Science Ltd.

Target

Axis Direct

Q1 revenue growth (10% YoY) was in line, but EBITDA declined 34% YoY (37% below our expectations) on lower gross margin of 50.2% (down 260 bps YoY). Gross margin declined due to (1) price erosion in key partnership products in US; delay in its key approvals

Number of FII/FPI investors decreased from 287 to 275 in Sep 2025 qtr

Strides Pharma Science Ltd.

14 Aug 2017

894.45

-0.56%

Strides Shasun Ltd Q1FY18 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue decreased by 5.25% to Rs. 841.77 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 5.25% to Rs. 841.77 Cr in Q1FY18 when compared to the previous quarter.

Number of FII/FPI investors decreased from 287 to 275 in Sep 2025 qtr

Is Strides Pharma Science Ltd. worth buying?

491 Votes:

Buy 78.82%

Sell 11.81%

Hold 9.37%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf